Remicade and Friends What You Need to Know Treating the Patient on TNF-alpha Inhibitors and Related Meds

Similar documents
Corporate Medical Policy

Cell-Mediated Immunity and T Lymphocytes

Cimzia. Cimzia (certolizumab pegol) Description

DISCLOSURES. Online A. Infectious Complications of Monoclonal Antibody Therapies 6/22/2012. Cytokine blocking. Lymphocyte depleting.

Outline. Biologic Drugs in Inflammatory Bowel Disease Dr. Jason Etzel MD The Vancouver Clinic. Biologic Drugs. Biologic Drugs. Biologic Drugs Anti-TNF

o Your healthcare provider should test you for TB before starting CIMZIA.

What prescribers need to know

Cimzia. Cimzia (certolizumab pegol) Description

Remicade (infliximab) DRUG.00002

Center for Evidence-based Policy

Cyltezo (adalimumab-adbm) CG-DRUG-64, CG-DRUG-65

Inflectra (infliximab-dyyb), Remicade (infliximab), Renflexis (infliximab-abda) DRUG CG-DRUG-64

Simponi / Simponi ARIA (golimumab)

Infliximab/Infliximab-dyyb DRUG.00002

HELPING YOU AND YOUR PATIENTS TALK OPENLY ABOUT MODERATELY TO SEVERELY ACTIVE RA

Cimzia. Cimzia (certolizumab pegol) Description

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

TUBERCULOSIS AND THE TNF-α INHIBITORS. Lloyd Friedman, M.D. Yale University Milford Hospital

Regulatory Status FDA-approved indication: Humira and Amjevita are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)

8/11/2015. Febrile neutropenia Bone marrow transplant Immunosuppressant medications

Amjevita (adalimumab-atto) CG-DRUG-64, CG-DRUG-65

Index. Note: Page numbers of article titles are in boldface type.

Remicade. Remicade (infliximab), Inflectra (infliximab-dyyb) Description

Regulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)

Stelara. Stelara (ustekinumab) Description

Remicade. Remicade (infliximab), Inflectra (infliximab-dyyb) Description

Steps TO HELP YOU TALK WITH YOUR DOCTOR ABOUT YOUR TREATMENT OPTIONS

KEEP UP THE FIGHT WITH. Little Victories

RHEUMATOID ARTHRITIS DRUGS

Synoviocytes. Macrophage. B cell C H R O N I C. Neutrophil. Mast cell I N F L A M M A T I O N. Tissue cell. Endothelial cell. Th1/Th17 IL17 IL22

Humira. (adalimumab) Drug Update Slideshow NEW INDICATION

VACCINATIONS AND INFLAMMATORY BOWEL DISEASE

Regulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of:

Stelara. Stelara (ustekinumab) Description

1 P a g e. Systemic Juvenile Idiopathic Arthritis (SJIA) (1.3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis.

CIMZIA (certolizumab pegol)

Humira (adalimumab) DRUG.00002

While every patient s experience is different, here are the general findings from clinical trials:

Psoriatic Arthritis- Secondary Care

MEDICATION GUIDE HUMIRA

Drugs and Applicable Coding: J-code: Enbrel-J1438; Humira-J0135; Remicade-J1745; Inflectra-Q5102; Cimzia-J0718; Simponi-J1602 Renflexis - pending

MEDICATION GUIDE. (tocilizumab)

Specialty Pharmacies: What they are. Why they are different.

Announcing HUMIRA. Psoriasis Starter Package

Get an Insurance Benefits Review for ORENCIA (abatacept)

Lecture: Rheumatology Update on DMARDs in Common Rheumatologic Diseases for the Family Physician. Sco Jay Harris, DO, FACFR

Corporate Medical Policy

PRIOR AUTHORIZATION REQUEST GUIDE

HUMIRA (adalimumab) injection, for subcutaneous use Initial U.S. Approval: 2002

The GPs role with biologics for immune-mediated inflammatory diseases David Gardner Rheumatologist GPCME 2015

Drug Class Review Targeted Immune Modulators

Immune Modulating Drugs Prior Authorization Request Form

Psoriatic Arthritis- Second Line Treatments

Dr. Lyubomir Marinchev Chief of Rheumatology Department, MHAT SOFIAMED, Sofia, Bulgaria

Corporate Medical Policy

Drug Class Review Targeted Immune Modulators

ESCMID Online Lecture Library. by author

HIGHLIGHTS OF PRESCRIBING INFORMATION

1 of 61. WARNING: SERIOUS INFECTIONS and MALIGNANCY See full prescribing information for complete boxed warning

Corporate Medical Policy

INFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Ixifi* (infliximabqbtx), Renflexis (infliximab-abda)

INFLECTRA (infliximab-dyyb) for injection

Drug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases

While every patient s experience is different, here are the general findings from clinical trials:

Are Biologicals Safe Enough?

IMPORTANT INFORMATION FOR HEALTHCARE PROFESSIONALS ON SAFETY AND RISK MINIMISATION FOR INFLIXIMAB

Regulatory Status FDA-approved indication: Humira is a tumor necrosis factor (TNF) blocker indicated for the treatment of: (2)

ORENCIA (oh-ren-see-ah) (abatacept)

Regulatory Status FDA-approved indication: Orencia is a selective T cell costimulation modulator indicated for: (1)

Biologics for Autoimmune Diseases

How do I choose amongst medicines for inflammatory bowel disease. Maria T. Abreu, MD

Tuberculosis and TNF Inhibitors

Cell Mediated Immunity CELL MEDIATED IMMUNITY. Basic Elements of Cell Mediated Immunity (CMI) Antibody-dependent cell-mediated cytotoxicity (ADCC)

JUST FOR KIDS SELECTED IMPORTANT SAFETY INFORMATION

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION

Proliferation of Medications

MEDICATION GUIDE XELJANZ (ZEL JANS ) (tofacitinib)

INFLECTRA. (infliximab-dyyb) for injection. Inflectra. Product information. Access and support

PART III: CONSUMER INFORMATION

DRAFT. Remission rates, calculated using observed case (OC) analyses were as follows: Year 1 Year 2 Year 3 Year 4 All patients 62.

1. Background: Infliximab is administered parenterally; therefore, it is not covered under retail pharmacy benefits.

Communicable Disease Control Manual Chapter 4: Tuberculosis

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

Corporate Medical Policy

Anti-TNF medication and tuberculosis

Guidelines for rheumatology patients on biologic therapy. Rheumatology Department Patient Information Leaflet

Antirheumatic drugs. Rheumatic Arthritis (RA)

Cimzia (certolizumab pegol) Data Showed Broad and Rapid Relief From Burden of Symptoms In Rheumatoid Arthritis Patients

PART III: CONSUMER INFORMATION

Jennifer Lam MPH candidate 2009 Johns Hopkins Bloomberg School of Public Health. Preceptors: Wendy Cronin, PhD MT(ASCP), Cathy Goldsborough, RN

First Name. Specialty: Fax. First Name DOB: Duration:

CYTOKINE AND CAM ANTAGONIST UTILIZATION IN MISSISSIPPI MEDICAID

5/9/2015. Disclosures. Infection in the (non-hiv) Immunocompromised Patient. Outline. Case #1. None. Critical Care Medicine May 2015

Priority Health Medicare prior authorization form Fax completed form to: toll free, or

PRODUCT MONOGRAPH REMICADE. Infliximab. Powder for Solution, Sterile, Lyophilized, 100 mg/vial. Biological Response Modifier

Drug Name (specify drug) Quantity Frequency Strength

INFLECTRA (infliximab-dyyb) Frequently Asked Questions. For Healthcare Professionals

Perioperative Medicine:

Transcription:

Remicade and Friends What You Need to Know Treating the Patient on TNF-alpha Inhibitors and Related Meds Scott Stienecker MD FACP FSHEA Medical Director for Epidemiology and Infection Prevention Parkview Health Office 266-1170, Cell 260-438-1426

Acknowledgements Some slides provided by: Michael Knipp, MD Qiagen Quest Oxford Immunotec Special thanks to: Dr. Richard B. Clark, PhD, D(ABMM) Scientific Director of Microbiology/Virology Quest Diagnostics Nichols Institute Dr. Michael Knipp MD, Parkview Occupational/Employee Health

Disclosures Nothing financial to disclose I am an Infusionist Board Member, Out-Patient IntraVenous Infusion Therapy Association (OPIVITA)

Biological Response Modifiers TNF-alpha Antagonists Etanercept (Enbrel) Infliximab (Remicade) Adalimumab (Humira) Certolizumab pegol (Cimzia) Golimumab (Simponi) Tysabri

What conditions? Rheumatoid arthritis Ulcerative colitis Crohn s disease Psoriasis Seronegative spondyloarthropathies (such as ankylosing spondylitis)

Biologics Adverse events reported Injection site reactions Infusion reactions Neutropenia Infections Demyelinating disease (17 cases) Heart failure Cutaneous reactions Malignancy (Hepatosplenic lymphoma) Induction of autoimmunity

Infectious Complications TB Mycobacterium avium Mycobacterium bovis Bacillus Calmette-Guerin Hepatitis A Hepatitis B Toxoplasma gondii Fungal infections Histoplasmosis Blastomycosis Coccidiomycosis Candida Aspergillus fumigatus Cryptococcus neoformans What do these infection have in common?

What are Helper T Cells? Pick up antigen from Macrophages Dendritic cells Presents to B Cells B Cells (CD19) become Plasma cells Plasma Cells make AB PMNs kill cells bound with antibody

Helper Cells Th1 Antiviral/Fungal/Bacteria Aggressive Promotes cytotoxic T-cell developement Anti-tumor I have never seen a case of Rheumatoid with Hep C Downside Psoriasis, UC, Crohn s, RA, Spondyloarthropathies (such as ankylosing spondylitis) Th2 Tolerant Downside Lymphoma, skin cancers Role in anti-parasite activity Increases associated with atopy and asthma

Cytotoxic T Cell Example: PPD, graft vs host CD4 pathway Example: Viral infection, bacterial infection www.vet.k-state.edu

www.bioscience.org

What do they do? Stimulate release of inflammatory cytokines interleukin IL- 1 beta, IL-6, IL-8 and GM-CSF Up regulate endothelial adhesion molecules, chemokines Coordinate the migration of leukocytes to targeted organs

TB Granuloma Note the palisade or picket fence appearance with central necrosis Histiocytes, or activated T cells prevent growth of the pathogen (TB in this case) Pleiad.umdnj.edu

Initial Screening TB Quantiferon gold or Tspot Fungal Infections (serum fungal battery or serum immunodiffusion panel) Hepatitis A total (vaccinate if negative) Hepatitis B Sab (vaccinate if negative) Hepatitis B Sag (hold treatment if positive) Hepatitis C Ab CBC/BMP/Hepatic profiles VZV Vaccine prior to initiation of TNF-inhibitor

At Risk for Infection Septic arthritis with Staph Aureus Listeriosis Legionella pneumonia Hep B/C Nocardia/non-TB bacteria TB Fungal (including histo/blasto/cocci/crypto/aspergillus) Pneumocystis

Screening and Vaccinations on Therapy TB Screen (PPD, Tspot, Quantiferon gold)--yearly Flu shot yearly Pneumovax at least once CBC/BMP/Hepatic profile every 6 months, more often if abnormalities are found, or if patient has evidence of brewing infection (unexplained fevers, weight loss, night sweats)

Controversies HPV vaccination TNF-alpha antibody monitoring Pneumovax ever 6 years HIB Prior PUVA increased risk of skin cancer COPD increased risk of cancer Live attenuated vaccines such as FluMist, VZV Vaccines, BCG increased risk of infection VZV vaccine Post-surgical healing and SSI What to do with Ortho patients?

TB occurring while on TNF-inhibitor therapy Stop TNF inhibitor until TB regimen started and patient condition improved. Optimal time to restart TNF inhibitor is undetermined Glucocorticosteroids during treatment for TB is considered safe MMWR August 5, 2004/53(30);683-686